Mobia Medical flags release on two-year VNS-REHAB Vivistim stroke recovery data publication

Mobia Medical, Inc.

Mobia Medical, Inc.

MOBI

0.00

  • Mobia Medical released a press statement on two-year VNS-REHAB follow-up data for Vivistim Paired VNS Therapy, published in Neurology.
  • Follow-up of 49 participants showed 76% met a clinically meaningful response on FMA-UE or WMFT; average gains were +7.5 FMA-UE, +0.63 WMFT.
  • Report cited sustained improvements in daily living measures, patient-reported quality of life; no therapy- or stimulation-related serious adverse events through two years.
  • Publication follows earlier pivotal results in The Lancet supporting FDA PMA in 2021; one-year data appeared in Stroke in 2025.
  • Study reference: two-year follow-up data link.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mobia Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607141618PRIMZONEFULLFEED9762208) on July 14, 2026, and is solely responsible for the information contained therein.